Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy
Received 16 September 2009; accepted 18 December 2009. published online 07 January 2010. Corrected Proof
Abstract
In the present study we developed doxorubicin-loaded solid lipid nanoparticles (SLN-Dox) using biocompatible compounds, assessed the in vitro hemolytic effect, and examined their in vivo effects on drug retention and apoptosis intensity in P-glycoprotein-overexpressing MCF-7/ADR cells, a representative Dox-resistant breast cancer cell line. Our SLNs did not show hemolytic activity in human erythrocytes. In comparison with Dox, SLN-Dox efficiently enhanced apoptotic cell death through the higher accumulation of Dox in MCF-7/ADR cells. Therefore, SLN-Dox have potential to serve as a useful therapeutic approach to overcome the chemoresistance of adriamycin-resistant breast cancer.
aBK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea
bDepartment of Pathology, College of Dentistry, Chosun University, Gwangju, South Korea
cResearch Center for Resistant Cells, Chosun University, Gwangju, South Korea
Corresponding author: College of Pharmacy, Chosun University, 375 Seosuk- dong, Dong-gu, Gwangju 501-759, South Korea.
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) through the Research Center for Resistant Cells (R13-2003-009).
ABSTRACT